Skip to content
Menu Close
Close button
Go back to News

Disc Medicine claims PhII win for repurposed ex-Roche drug in rare blood disorder

When Disc Medicine closed a $62.5 million raise led by Bain Capital earlier this year, the biotech’s CEO John Quisel pointed to the stream of clinical readouts in blood disorders it is expecting as the impetus.

disc medicine